Federica Tomao
Federica Tomao is an expert in Oncology at Policlinico Umberto I (Italy). As of October 2026, ScienceLeadR ranks Federica Tomao in the top 1% of experts worldwide for Urogenital Neoplasms and Genital Neoplasms, Female. Federica Tomao has authored 200 publications, the most recent in 2026, and is an investigator in 6 clinical trials, 3 of them ongoing. SLR score: 664 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Gynecology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2006 - 2026
Number : 200
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Fertility preservation and reproductive outcomes in young women with breast and gynecological cancers: a new challenge for the clinician. PMID 42828140 — cancer survivors, pregnancy, fertility, parturition, breast neoplasms, ovary, fertility preservation, neoplasms, cryopreservation, breast, therapeutics, counseling | Front Oncol | 2026 | 0 |
| Transperineal Ultrasound in Chronic Pelvic Pain: A Systematic Review. PMID 42735087 — pain, ultrasonography, pelvic pain | J Clin Ultrasound | 2026 | 0 |
| The Microbiota as a Potential Cause of Disease. PMID 42505588 — diabetes mellitus, aging, cardiovascular diseases, diet, osteoporosis, gastrointestinal microbiome, microbiota, diabetes mellitus, type 2 | Diseases | 2026 | 0 |
| Antibody-drug conjugates: a practical review on clinical management of toxicities. PMID 42234409 — pharmaceutical preparations, drug-related side effects and adverse reactions | Expert Rev Anticancer Ther | 2026 | 0 |
| Clinical relevance and prognostic role of PDL-1 expression in cervical cancer patients. PMID 42104993 — uterine cervical neoplasms, neoplasms | Arch Gynecol Obstet | 2026 | 0 |
Clinical Studies 6
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A CLINICAL TRIAL TO CONFIRM THE EFFICACY OF OLAPARIB IN COMBINATION WITH BEVACIZUMAB ADMINISTERED AS MAINTENANCE THERAPY AFTER A FRONTLINE PLATINUM BASED CHEMOTHERAPY PLUS BEVACIZUMAB IN THE TREATMENT OF PATIENTS WITH OVARIAN TUMOURS SHOWING A GENETIC DEFECTS IN A DNA REPAIR MECHANISM CALLED HOMOLOGOUS RECOMBINATION (DEFINED AS HRD POSITIVE WHERE HRD MEANS HOMOLOGOUS RECOMBINATION DEFICIENCY) 2022-502242-27-00 — recombination, genetic, dna repair, homologous recombination, dna, a-form, ovary, neoplasms, bevacizumab, biopsy, drug therapy, maintenance, peritoneal neoplasms, therapeutics, genes, brca1, dna, fallopian tubes, chemotherapy | Phase 4 | Active not recruiting | 2023 |
| First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients NCT06121401 — ovary, neoplasms, bevacizumab, tablets, drug therapy, maintenance, body weight, therapeutics, carcinoma, ovarian epithelial, chemotherapy, carcinoma | Phase 4 | Active not recruiting | 2023 |
| Adjuvant Therapy in POLE Mutated and p53 Wildtype NSMP Early Stage Endometrial Cancer RAINBO BLUE TAPER NCT05640999 — radiotherapy, brachytherapy, neoplasms, radiotherapy, adjuvant, therapeutics, endometrial neoplasms | Phase 2 | Recruiting | 2022 |
LeadR Networks
Main global connection map